Posted by Michael Wonder on 07 Dec 2024
Lantern Pharma's investigational drug candidate, LP-184, receives second fast track designation from FDA for treatment of triple negative breast cancer
3 December 2024 - LP-184 has demonstrated significant pre-clinical efficacy in triple negative breast cancer models, including those resistant to PARP inhibitors, and recent data shows promising synergy with checkpoint inhibitors in triple negative breast cancer.
Lantern Pharma today announced that the FDA has granted fast track designation for investigational drug candidate, LP-184, for treatment of triple negative breast cancer.
